Pfizer to present data across its pain and inflammation portfolio

Pfizer has announced data from across its pain and inflammation portfolio is due to be presented at the American College of Rheumatology (ACR), which takes place in San Francisco from October 25th to 29th.

The company adds late-breaking abstracts for its investigational JAK-inhibitor CP-690,550 and Celebrox celecoxib capsules will also be made available at the ACR symposium.

Data on a number of compounds which represent “potential new mechanisms targeting pain and inflammation” will be presented, including a key pain mediator, a new molecule which is designed to target nerve growth factor and a highly selective norepinephrine reuptake inhibitor.

The latter upregulates the activity of this important neurotransmitter, Pfizer adds.

Dr Ethan Weiner, development head for inflammation at the company, states there is a need for new medications to address the disability, pain and underlying progression of disease of inflammatory conditions.

“We are very excited to present data on CP-690,550, our JAK-inhibitor, and lead compound in development for rheumatoid arthritis, as well as tanezumab, a compound that may offer a novel way of treating osteoarthritis pain at the upcoming ACR meeting,” he adds.

In recent weeks, Pfizer announced it had been honoured by the US Environmental Protection Agency for its energy and climate change programme, which reduced total greenhouse gas emissions by 43 per cent per million dollars of revenue from 2000 to 2007.